FDA Liked What It Saw In Kalydeco’s Development Program
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Agency reviewers looked favorably upon the pivotal trials’ primary efficacy endpoint and low drop-out rate, as well as the overall quality of the NDA submission.
You may also be interested in...
Bronchitol AdComm Shows Difficulty Of Following In Kalydeco’s Shadow
Comparisons between the robustness of the efficacy data for dry powder mannitol and Vertex’s ivacaftor were difficult for FDA to avoid during the Pulmonary-Allergy Drugs Advisory Committee’s Jan. 30 review of Pharmaxis’ cystic fibrosis drug.
FDA’s First Breakthrough Designations Continue Vertex Kalydeco’s Regulatory Successes
Label expansion efforts for Vertex’s cystic fibrosis therapy will be claims taken through FDA’s new review pathway; the initial product could reach more patients more quickly and serve as a guide to how the agency will handle drugs earmarked for streamlined development and approval.
FDA’s First Breakthrough Designations Continue Vertex Kalydeco’s Regulatory Successes
Label expansion efforts for Vertex’s cystic fibrosis therapy will be claims taken through FDA’s new review pathway; the initial product could reach more patients more quickly and serve as a guide to how the agency will handle drugs earmarked for streamlined development and approval.